Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4208-4214

  He, Ran ^a   Forman, Michael ^a   Mott, Bryan T ^b   Venkatadri, Rajkumar ^a   Posner, Gary H ^a,b   Arav Boger, Ravit ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ DERIVATIVE; ARTESUNATE; CYTOMEGALOVIRUS ANTIGEN PP65; DIMER 838; GANCICLOVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; ARTEMISININS; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; DIMERIZATION; DNA, VIRAL; FIBROBLASTS; GENES, REPORTER; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LUCIFERASES; ORGANOPHOSPHATES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84882367844     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00893-13     Document Type: Article

References (19)

1. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. 2004. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363:9-17.
2. Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. 2008. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 47:804-811.
3. Efferth T, Marschall M, Wang X, Huong SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T, Huang ES. 2002. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J. Mol. Med. 80:233-242.
4. Kaptein SJ, Efferth T, Leis M, Rechter S, Auerochs S, Kalmer M, Bruggeman CA, Vink C, Stamminger T, Marschall M. 2006. The antimalaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res. 69:60-69.
5. Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T, Caplan O, Saleh N, Efferth T, Marschall M, Wolf DG. 2008. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis. 46:1455-1457.
6. Wolf DG, Shimoni A, Resnick IB, Stamminger T, Neumann AU, Chou S, Efferth T, Caplan O, Rose J, Nagler A, Marschall M. 2011. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res. 90:183-186.
7. Chou S, Marousek G, Auerochs S, Stamminger T, Milbradt J, Marschall M. 2011. The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antiviral Res. 92:364-368.
8. Lau PK, Woods ML, Ratanjee SK, John GT. 2011. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin. Infect. Dis. 52:279.
9. Ribeiro IR, Olliaro P. 1998. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med. Trop. (Mars.) 58(3 Suppl):50-53.
10. Arav-Boger R, He R, Chiou CJ, Liu J, Woodard L, Rosenthal A, Jones-Brando L, Forman M, Posner GH. 2010. Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers. PLoS One 5:e10370. doi:10.1371/journal.pone .0010370.
11. He R, Mott BT, Rosenthal AS, Genna DT, Posner GH, Arav-Boger R. 2011. An artemisinin-derived dimer has highly potent anticytomegalovirus (CMV) and anti-cancer activities. PLoS One 6:e24334. doi:10.1371/journal.pone.0024334.
12. He R, Park K, Cai H, Kapoor A, Forman M, Mott B, Posner GH, Arav-Boger R. 2012. Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 56:3508-3515.
13. Alagbala AA, McRiner AJ, Borstnik K, Labonte T, Chang W, D'Angelo JG, Posner GH, Foster BA. 2006. Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines. J. Med. Chem. 49:7836-7842.
14. He R, Sandford G, Hayward GS, Burns WH, Posner GH, Forman M, Arav-Boger R. 2011. Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors. Virol. J. 8:40.
15. Tanaka Y, Kanda Y, Kami M, Mori S, Hamaki T, Kusumi E, Miyakoshi S, Nannya Y, Chiba S, Arai Y, Mitani K, Hirai H, Mutou Y. 2002. Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant. 30:315-319.
16. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, Shen L, Siliciano RF. 2012. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat. Med. 18:446-451.
17. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. 2001. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 18:767-773.
18. Posner GH, Ploypradith P, Parker MH, O'Dowd H, Woo SH, Northrop J, Krasavin M, Dolan P, Kensler TW, Xie S, Shapiro TA. 1999. Antimalarial, antiproliferative, and antitumor activities of artemisininderived, chemically robust, trioxane dimers. J. Med. Chem. 42:4275-4280.
19. Efferth T. 2007. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Med. 73: 299-309.